Flora Growth与大麻巨头Canopy联手进入价值9400万美元的澳大利亚医用大麻市场-动脉网

Flora Growth Teams Up With Cannabis Giant Canopy To Enter $94M Australian Medical Marijuana Market

benzinga 等信源发布 2024-10-15 09:28



可切换为仅中文







Flora Growth Corp. FLGC signed a distribution agreement with Canopy Growth Corp. CGC for the distribution of Canopy’s Storz & Bickel medical line of vaporizers in Australia. Flora's subsidiary Australian Vaporizers will be in charge of distribution.

Flora Growth Corp.FLGC与Canopy Growth Corp.CGC签署了一份分销协议，用于在澳大利亚分销Canopy的Storz&Bickel医疗系列蒸发器。Flora的子公司澳大利亚汽化器将负责分配。

“Canopy Growth is a market leader with a $400 million market capitalization. We are very much interested in partnering with Canopy Growth to bring their highly regarded Storz vaporizers to the Australian market,” stated Clifford Starke, chairman and chief executive officer. “With Australian Vaporizers at the forefront of this initiative, we are confident that our distribution of Canopy’s Storz products will further enhance the standard of care for medical cannabis patients in Australia.”.

董事长兼首席执行官克利福德·斯塔克（CliffordStarke）表示：“冠层增长（Canopy Growth）是一家市值4亿美元的市场领导者。我们非常有兴趣与冠层增长（Canopy Growth）合作，将其备受推崇的Storz汽化器推向澳大利亚市场。”。“由于澳大利亚汽化器处于这一举措的前沿，我们相信，我们对Canopy Storz产品的分销将进一步提高澳大利亚医用大麻患者的护理标准。”。

Australian Vaporizers will spearhead the distribution of Storz vaporizers to healthcare professionals and clinics across the country. This agreement will enable Flora to meet the growing demand for various medical cannabis consumption solutions and further advance the company's position in the burgeoning Australian medical marijuana industry.

澳大利亚汽化器公司将率先向全国的医疗保健专业人员和诊所销售Storz汽化器。该协议将使Flora能够满足对各种医用大麻消费解决方案日益增长的需求，并进一步提升该公司在新兴的澳大利亚医用大麻行业中的地位。

According to Grand View Research, the Australian medical cannabis market size was estimated at $94 million and is projected to grow at a CAGR of 33.6% from 2024 to 2030..

据大视野研究公司（Grand View Research）估计，澳大利亚医用大麻市场规模为9400万美元，预计2024年至2030年的复合年增长率将达到33.6%。。

Canopy Growth’s Storz vaporizers are designed specifically to meet the needs of the medical cannabis community, focusing on patient safety and offering some of the most innovative products on the market. Each device is built with precision for optimal dosing and efficiency to ensure users receive a consistent and controlled experience..

Canopy Growth的Storz汽化器专为满足医用大麻社区的需求而设计，专注于患者安全，并提供市场上一些最具创新性的产品。每台设备都具有最佳剂量和效率的精确度，以确保用户获得一致和受控的体验。。

Read Also: ‘The Whole World Is In Overdose,’ Says CEO Of Company Behind Cannabis Inhaler That Enables Controlled Dosing

另请阅读：“整个世界都在过量服用，”大麻吸入器公司的首席执行官说，大麻吸入器可以控制剂量

Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.

每天在收件箱中免费获取Benzinga的独家分析以及有关大麻行业和市场的热门新闻。在此处订阅我们的新闻稿。如果你认真对待这项业务，你就不能错过。

Flora Growth's Recent Milestones

植物群生长的最新里程碑

The news follows up on Flora Growth's recent moves across Europe, such as an exclusive distribution deal with Canapuff, a Czech Republic-based provider of cannabinoid consumer products. This partnership will introduce Flora's Vessel brand of cannabis accessories into the Czech market, one of Central Europe's most progressive..

这则新闻是Flora Growth最近在欧洲采取行动的后续报道，例如与捷克共和国大麻素消费品供应商Canapuf达成独家经销协议。这一合作关系将把Flora的船用大麻配件品牌引入捷克市场，这是中欧最先进的市场之一。。

The company also recently signed a supply agreement with Blossom Genetics to bring Colombian medical cannabis to the German market.This collaboration will introduce two strains, Chemmy Jones and Northern Lights, to the European country. The move follows the company’s recent acquisition of Germany-based TruHC Pharma GmbH in response to the country's recent cannabis reform..

该公司最近还与Blossom Genetics签署了一份供应协议，将哥伦比亚医用大麻推向德国市场。这项合作将向欧洲国家引入两种菌株，Chemmy Jones和Northern Lights。此前，该公司最近收购了总部位于德国的TruHC Pharma GmbH，以应对该国最近的大麻改革。。

FLGC Price Action

FLGC价格行动

Flora Growth shares closed Monday's market session 8.87% lower at $1.85 per share.

Flora Growth股价周一收盘下跌8.87%，至每股1.85美元。